What the Comments Reveal (Beyond Views & Likes)
3.2M views and 70K likes on “Truth Behind Ozempic Weight Loss Trend ft. My Wife” by Doctor Gary Linkov, as of October 9, 2025. From 5,376 total comments, we analyzed a 1,000-comment sample to uncover what truly engaged viewers are saying.
Sentiment Snapshot
The tone of conversation is predominantly positive, reflecting trust and gratitude toward the doctors and the video’s balanced approach to the Ozempic topic.
Emotional Pulse: Grateful Leads the Way
Viewers expressed strong gratitude and admiration for the honest, science-based delivery, with curiosity and amusement rounding out the mix—showing that even complex medical topics can be engaging when communicated transparently.
Comment Breakdown: Compliments and Complaints Dominate
A healthy mix of praise, personal stories, and constructive criticism—indicating both appreciation and active curiosity from an informed audience.
Gary Linkov’s Engagement in the Comments
Roughly 1 in 17 commenters received a heart or reply, showing selective but meaningful engagement. Increasing responses could further strengthen viewer trust and retention.
Burning Questions
Viewers want clarity on how to choose between Ozempic, Wegovy, and Saxenda—especially for those who are overweight but not diabetic. They’re eager to understand why Ozempic is used off-label, how the drugs differ in cost, safety, and long-term outcomes, and whether results can be maintained post-treatment.
Questions also span side effects, hypoglycemia risk in non-diabetics, emotional and craving changes, and access issues tied to off-label use. Many seek science-based answers on lab monitoring, safe tapering, and how to mimic GLP-1 benefits naturally through diet and exercise.
Feedback and Critiques
Audiences praised the video’s clarity, balance, and compassion—calling it one of the most trustworthy explanations on GLP-1 drugs. Many felt empowered to make informed choices and appreciated the body-positive, ethical framing. The partnership between the doctors was noted as authentic and credible.
Critiques centered on access, pricing, and risk nuance. Some expressed frustration about off-label demand affecting diabetic supply, high U.S. prices, and lack of detail on potential complications like nausea, anesthesia effects, and muscle loss. Others requested deeper exploration of vitamin D, kidney function, and lifestyle integration.
High Praise
Viewers consistently described this video as exceptionally informative and transparent. They commended Dr. Linkov’s ability to explain complex medical concepts in clear, relatable language, while maintaining scientific precision and integrity.
Dr. Liz’s presence drew strong admiration for her empathy and clarity. Many celebrated their chemistry as a “power couple” delivering both authority and warmth—creating content that informs, reassures, and builds genuine trust.
Opportunities for Future Content
- Should I start a GLP-1? A step-by-step candidacy checklist and lab work-up.
- GLP-1s and low blood sugar: the real risk for non-diabetics and people with reactive hypoglycemia.
- Mind and metabolism: GLP-1s, mood, and cravings beyond food.
- Life on (and after) GLP-1s: preventing weight regain and protecting muscle.
- The practical guide: cost, access, and safety logistics.
- Medicine vs trend: access, equity, and body image with Dr. Liz.
Wrapping Up
This video’s success lies in its clarity, compassion, and ethical framing. Strengthening direct engagement and addressing detailed viewer concerns—especially around long-term effects and access—could elevate trust even further. Shono AI turns these signals into actionable insights for creators ready to listen deeper.
About This Analysis
Methodology & Limits
We analyzed 1,000 representative comments from a total of 5,376, removing spam and duplicates. AI models categorized each by sentiment, emotion, and type before aggregating results into this snapshot.
Engagement rates reflect the sampled set only. Snapshot as of October 9, 2025; values may shift as new comments arrive.
